L-arginine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: L-arginine
• 英文别名: L-argininal；Argininal；2-[(4S)-4-amino-5-oxopentyl]guanidine
• 化学式: C₆H₁₄N₄O
• 分子量: 158.203
• InChiKey: QJYRUYURLPTHLR-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  二氧化碳 、 L-arginine 以 水 为溶剂， 10.0 ℃ 、103.42 kPa 条件下， 反应 0.08h， 生成 L-arginine bicarbonate
  参考文献：
  名称：

  WO2009/100267

  摘要：

  公开号：
• 作为产物：
  描述：

  (2S)-2-氨基-5-(二氨基亚甲基氨基)戊酸甲酯二盐酸盐 在 盐酸 、 sodium amalgam 作用下， 以 水 为溶剂， 生成 L-arginine
  参考文献：
  名称：

  Second generation 2-aminoimidazole based advanced glycation end product inhibitors and breakers

  摘要：

  The formation of advanced glycation end-products (AGE) as a result of the action of reducing sugars on host macromolecules plays a role in increased morbidity of diabetic patients. There are currently no clinically available therapeutics for the prevention or eradication of AGEs. Following our previous identification of 2-aminoimidazole (2-AI) based AGE inhibitors and breakers, we now report the use of a rapid, scalable, two-step procedure to access a second generation of 2-AI based anti-AGE compounds from commercially available amino acids. Several second generation compounds exhibit increased AGE inhibition and breaking activty compared to the first generation compounds and to the known AGE inhibitor aminoguanidine. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.06.080
• 作为试剂：
  描述：

  barium(II) nitrate 、 sodium fluoride 、 dysprosium nitrate 、 gadolinium(III) nitrate 在 L-arginine 作用下， 以 水 为溶剂， 反应 25.83h， 生成
  参考文献：
  名称：

  Magnetic-downconversion luminescent bifunctional BaGdF₅:Dy³⁺,Eu³⁺ nanospheres: energy transfer, multicolor luminescence and paramagnetic properties

  摘要：

  通过采用不同的激发波长，在 Dy3+ 和 Eu3+ 共激活的 BaGdF5 荧光中获得了可调色和白光发射。同时，所获得的样品在室温和低温下也表现出顺磁性能。

  DOI：

  10.1039/c6ra09754e

文献信息

• Mandelic acid derivatives and their use as throbin inhibitors
  申请人：——

  公开号：US20040019033A1

  公开（公告）日：2004-01-29

  There is provided a compound of formula I 1 wherein R a , R 1 , R 2 , Y and R 3 have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

  提供了一种公式I的化合物 1 其中R a , R 1 , R 2 , Y和R 3 具有说明书中给出的含义以及药学上可接受的衍生物（包括前药），这些化合物和衍生物可用作竞争性胰蛋白酶样蛋白酶抑制剂，如凝血酶，因此，特别是用于需要抑制凝血酶的情况（例如血栓形成）或作为抗凝剂。
• Composition for the treatment of damaged tissue
  申请人：Pfizer Inc.

  公开号：US20030199440A1

  公开（公告）日：2003-10-23

  A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.

  描述了一种用于受损组织，如伤口治疗（例如愈合）的药物。该药物包括包含以下成分的组合物：（a）生长因子；和（b）抑制剂；以及可选的（c）药用载体、稀释剂或赋形剂；其中抑制剂可以抑制至少一种在受损组织，如伤口环境中上调的特定不良蛋白质（例如特定蛋白酶）的作用。
• Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof
  申请人：Stürzebecher Jörg

  公开号：US20070066539A1

  公开（公告）日：2007-03-22

  The invention relates to the novel base-substituted benzylamine analogs of general formula (I), wherein A represents P 2 -P 1 with P 1 =(A) and P 2 =(B), for use as coagulation factor Xa inhibitors. The invention also relates to the production and use of said analogs in the therapy and prophylaxis of cardiovascular diseases and thromboembolic events.

  该发明涉及一般式（I）的新型基取代苄胺类似物，其中A代表P2-P1，P1=(A)和P2=(B)，用作凝血因子Xa抑制剂。该发明还涉及所述类似物的制备和在心血管疾病和血栓栓塞事件的治疗和预防中的应用。
• Thiochromane derivatives and their use as thrombin inhibitors
  申请人：——

  公开号：US20030220317A1

  公开（公告）日：2003-11-27

  There is provided compounds of formulae I and IA 1 wherein Y, R 1 , R 2 , R 3 , D 1 and D 2 have meanings given in the description which are useful as, or as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

  提供了具有公式I和IA1的化合物，其中Y、R1、R2、R3、D1和D2的含义如描述中所述，这些化合物可用作竞争性蛋白酶抑制剂，如凝血酶等，尤其在需要抑制凝血酶的情况下（如血栓形成）或作为抗凝剂。
• New amidino derivatives and their use as thormbin inhibitors
  申请人：——

  公开号：US20020068730A1

  公开（公告）日：2002-06-06

  There is provided compounds of formula I, 1 wherein Y and R 1 have meanings given in the description, and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

  提供了化合物I，其中Y和R1的含义如描述中所述，并且其药学上可接受的衍生物（包括前药），这些化合物和衍生物在竞争性蛋白酶酶类（如凝血酶）的抑制剂方面具有用处，因此特别适用于治疗需要抑制凝血酶的情况（例如血栓形成）或作为抗凝剂。